Market Place
Sourcing Support
Stoke Therapeutics at 25th Needham Healthcare Conference
08 Apr 2026 //
PHARMIWEB
Stoke Therapeutics Presents At TD Cowen Health Care Conference
24 Feb 2026 //
BUSINESSWIRE
Stoke Therapeutics Grants Inducements Under Nasdaq Rule 5635(c)
18 Feb 2026 //
BUSINESSWIRE
Stoke Therapeutics Doses First Patient in STK-002 Trial
11 Feb 2026 //
PHARMIWEB
Stoke Therapeutics To Present At Guggenheim Biotech Summit 2026
04 Feb 2026 //
BUSINESSWIRE
Anchor Line Partners Secures 98,500 Sq-Ft Lease For Stoke
27 Jan 2026 //
PR NEWSWIRE
Stoke Therapeutics Announces Nasdaq Inducement Grants LR
16 Jan 2026 //
BUSINESSWIRE
Stoke Therapeutics Announces Updates of Zorevunersen
11 Jan 2026 //
PHARMIWEB
Stoke Therapeutics To Present At JP. Morgan Healthcare Conference
06 Jan 2026 //
BUSINESSWIRE
Stoke Therapeutics Inducement Grants per Nasdaq Rule 5635(c)(4)
17 Dec 2025 //
PHARMIWEB
Stoke Therapeutics Grants Inducements Under Nasdaq Listing Rule
16 Dec 2025 //
BUSINESSWIRE
Biogen, Stoke Enhance Epilepsy Drug`s Blockbuster Potential
08 Dec 2025 //
BIOSPACE
China Adds LEQEMBI to National Drug Reimbursement List
08 Dec 2025 //
GLOBENEWSWIRE
Biogen, Stoke Announce Presentations at 2025 AES Annual Meeting
01 Dec 2025 //
GLOBENEWSWIRE
Stoke Therapeutics Awards Inducement Grants Nasdaq LR
18 Nov 2025 //
BUSINESSWIRE
Stoke Therapeutics To Present at Guggenheim Healthcare
05 Nov 2025 //
BUSINESSWIRE
Stoke Therapeutics Unveils Q3 2025 Financials & Business Update
04 Nov 2025 //
BUSINESSWIRE
Stoke Therapeutics to Discuss Q3 2025 Business and Financial
30 Oct 2025 //
BUSINESSWIRE
Stoke Therapeutics Issues Inducement Grants Per Nasdaq LR
16 Oct 2025 //
PHARMIWEB
Stoke Therapeutics, Biogen Unveil Zorevunersen Data at Meeting
09 Oct 2025 //
BUSINESSWIRE
Stoke Therapeutics Names Ian F. Smith CEO
06 Oct 2025 //
PHARMIWEB
Stoke Therapeutics Issues Inducement Grants per Nasdaq LR
16 Sep 2025 //
PHARMAWEB
Stoke, Biogen Present Zorevunersen Data In Dravet Syndrome
25 Aug 2025 //
PHARMAWEB
Stoke, Biogen Unveil Zorevunersen Data for Dravet Syndrome
10 Jul 2025 //
BUSINESSWIRE
Stoke Therapeutics to Present at Jefferies Healthcare Conference
29 May 2025 //
BUSINESSWIRE
Stoke Therapeutics Reports Q1 2025 Financial Results & Updates
13 May 2025 //
BUSINESSWIRE
Stoke Therapeutics to Present at Needham Healthcare Conference
01 Apr 2025 //
BUSINESSWIRE
Stoke Therapeutics To Present At Investor Conferences In March
26 Feb 2025 //
BUSINESSWIRE
Stoke Therapeutics to Present at 43rd Annual J.P. Morgan Conference
08 Jan 2025 //
BUSINESSWIRE
Stoke Gets FDA Breakthrough Designation For Zorevunersen In Dravet
04 Dec 2024 //
BUSINESSWIRE
Stoke Therapeutics to Data on Zorevunersen for Dravet Syndrome
02 Dec 2024 //
BUSINESSWIRE
Stoke Presents Zorevunersen Data For Dravet Syndrome
10 Sep 2024 //
BUSINESSWIRE
Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
04 Sep 2024 //
BUSINESSWIRE
Stoke Therapeutics to Present Data on Zorevunersen at European Epilepsy Congress
03 Sep 2024 //
BUSINESSWIRE
Stoke Therapeutics to Present at Upcoming Investor Conferences in September
03 Sep 2024 //
BUSINESSWIRE
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
16 Aug 2024 //
BUSINESSWIRE
Stoke Therapeutics Reports Q2 Results And Provides Business Updates
07 Aug 2024 //
BUSINESSWIRE
Stoke`s Dravet Syndrome Med Released From Partial Clinical Hold
07 Aug 2024 //
FIERCE BIOTECH
Stoke Announces Data of the STK-001 for the Treatment of Dravet Syndrome
25 Mar 2024 //
BUSINESSWIRE
Stoke Presents Data Related to the Ongoing Clinical Development of STK-001
05 Sep 2023 //
BUSINESSWIRE
Stoke to Host Webinar to Present New Data from Patients Treated with STK-001
21 Jul 2023 //
BUSINESSWIRE
Stoke Reports First Quarter Financial Results and Provides Business Updates
04 May 2023 //
PRESS RELEASE
Stoke Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001
15 Mar 2023 //
BUSINESSWIRE
